GAMMA Investing’s Esperion Therapeutics ESPR Stock Holding History

GAMMA Investing’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-141	Closed	-$446	–	4353
2026 Q2	$446	Buy	141 +71	+101%	+$199	﹤0.01%	4002
2026 Q1	$192	Sell	70 -453	-87%	-$1.43K	﹤0.01%	4061
2025 Q4	$1.94K	Buy	+523	New	+$1.69K	﹤0.01%	3608

GAMMA Investing's ESPR Position: Q3 2026 in Review

GAMMA Investing sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 141 shares — an estimated $446 sold.

GAMMA Investing first reported a position in ESPR in Q4 2025 and held it in 3 quarters. The position peaked at $1.94K in Q4 2025. 0 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

GAMMA Investing reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
GAMMA Investing sold 141 Esperion Therapeutics shares in Q3 2026, an estimated $446.
GAMMA Investing first reported a position in Esperion Therapeutics in Q4 2025 and held it in 3 quarters.
GAMMA Investing's Esperion Therapeutics position peaked at $1.94K in Q4 2025.
0 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.